Evidence map›Paper›PMID 41994014›Full record

ArticleESMO gastrointestinal oncology2026

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer.

T Wakatsuki, T Mashima, N Miyazaki, H Osumi, S Fukuoka, A Ooki, K Shimozaki, M Ogura, K Yoshino, S Udagawa and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

T WakatsukiDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
T MashimaDivision of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
N MiyazakiDivision of Data Science, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
H OsumiDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
S FukuokaDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
A OokiDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
K ShimozakiDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
M OguraDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
K YoshinoDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
S UdagawaDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
E ShinozakiDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
K ChinDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
N IshidaDivision of Data Science, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
H SeimiyaDivision of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
K YamaguchiDepartment of Gastrointestinal Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Plasma vascular endothelial growth factor-A (VEGF-A) concentrations markedly increased immediately after ramucirumab administration, and the high VEGF-A concentrations were significantly associated with worse outcomes in advanced gastric cancer. In a preclinical study, combination therapy with anti-VEGF-A and anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibodies showed superior tumor suppression compared with monotherapy, suggesting dual VEGF-A/VEGFR2 blockade may be a promising therapeutic strategy. Design: The BevRam-GC01 trial is a phase I trial evaluating the tolerability and safety of bevacizumab biosimilar (5 or 10 mg/kg) plus ramucirumab (8 mg/kg) and paclitaxel (80 mg/m

Indexed as

angiogenesisimmune remodelingtumor microenvironmentVEGF-AVEGFR2

Identifiers

PMID41994014
PMCPMC13080813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.